Hemostasis Today

September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Mar 13, 2026, 16:44

Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Lana Castellucci et al, adding:

“Important paper for clinical practice.

A large study, independent of the pharma industry, found that in the setting of acute venous thrombosis, the risk of clinically relevant bleeding was:

  • 3.3 percent with Apixaban
  • 7.3 percent with Rivaroxaban

This difference was significant.

Congratulations to Lana Castellucci for coordinating this multicentre study.

We await the results of their AF study with interest.

Considering how many patients worldwide are on these drugs, this will be an impactful study.

The attached figure gives the summary.

The original article in this week’s New England Journal of Medicine is behind a paywall.”

Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger

Read the Full Article on The New England Journal of Medicine

Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis

Stay updated on all scientific advances with Hemostasis Today.